rabeprazole has been researched along with Abdominal Pain in 5 studies
Rabeprazole: A 4-(3-methoxypropoxy)-3-methylpyridinyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.
Abdominal Pain: Sensation of discomfort, distress, or agony in the abdominal region.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Evaluate the efficacy and safety of rabeprazole in children, 1 to 11 years old, with endoscopically/histologically proven gastroesophageal reflux disease (GERD)." | 9.17 | Efficacy and safety of rabeprazole in children (1-11 years) with gastroesophageal reflux disease. ( Haddad, I; Hu, P; Kierkus, J; Leitz, G; Silber, S; Sloan, S; Tron, E; Ulmer, A, 2013) |
| "The aims of the study are to clarify the pathophysiological differences among early chronic pancreatitis (ECP), functional dyspepsia with pancreatic (FD-P) enzyme abnormalities and FD patients and to determine whether camostat mesilate, pancrelipase, and rabeprazole triple therapy improve FD symptoms in the ECP patients and FD-P patients in cross-over way." | 7.91 | Camostat Mesilate, Pancrelipase, and Rabeprazole Combination Therapy Improves Epigastric Pain in Early Chronic Pancreatitis and Functional Dyspepsia with Pancreatic Enzyme Abnormalities. ( Agawa, S; Futagami, S; Gudis, K; Higuchi, K; Iwakiri, K; Kaneko, K; Kawamoto, C; Kodaka, Y; Murakami, M; Sakasegawa, N; Ueki, N; Wakabayashi, M; Yamawaki, H, 2019) |
| "The aim of this study is to clarify whether acotiamide and rabeprazole combination therapy can improve clinical symptoms, gastric emptying, and satisfaction with treatment in functional dyspepsia (FD) patients more effectively than acotiamide or rabeprazole monotherapy alone." | 5.22 | Improvement of meal-related symptoms and epigastric pain in patients with functional dyspepsia treated with acotiamide was associated with acylated ghrelin levels in Japan. ( Akamizu, T; Futagami, S; Gudis, K; Hashimoto, S; Iwakiri, K; Kawagoe, T; Kodaka, Y; Maruki, Y; Nagoya, H; Sakamoto, C; Sato, H; Yamawaki, H, 2016) |
| "The aim of the present study was to evaluate 24-week maintenance of efficacy and safety of rabeprazole in children with endoscopically proven gastroesophageal reflux disease (GERD)." | 5.19 | Maintenance of efficacy and safety of rabeprazole in children with endoscopically proven GERD. ( Haddad, I; Hu, P; Kierkus, J; Leitz, GJ; Silber, S; Sloan, S; Tron, E; Ulmer, A, 2014) |
| "Evaluate the efficacy and safety of rabeprazole in children, 1 to 11 years old, with endoscopically/histologically proven gastroesophageal reflux disease (GERD)." | 5.17 | Efficacy and safety of rabeprazole in children (1-11 years) with gastroesophageal reflux disease. ( Haddad, I; Hu, P; Kierkus, J; Leitz, G; Silber, S; Sloan, S; Tron, E; Ulmer, A, 2013) |
| "The aims of the study are to clarify the pathophysiological differences among early chronic pancreatitis (ECP), functional dyspepsia with pancreatic (FD-P) enzyme abnormalities and FD patients and to determine whether camostat mesilate, pancrelipase, and rabeprazole triple therapy improve FD symptoms in the ECP patients and FD-P patients in cross-over way." | 3.91 | Camostat Mesilate, Pancrelipase, and Rabeprazole Combination Therapy Improves Epigastric Pain in Early Chronic Pancreatitis and Functional Dyspepsia with Pancreatic Enzyme Abnormalities. ( Agawa, S; Futagami, S; Gudis, K; Higuchi, K; Iwakiri, K; Kaneko, K; Kawamoto, C; Kodaka, Y; Murakami, M; Sakasegawa, N; Ueki, N; Wakabayashi, M; Yamawaki, H, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yamawaki, H | 2 |
| Futagami, S | 2 |
| Kaneko, K | 1 |
| Agawa, S | 1 |
| Higuchi, K | 1 |
| Murakami, M | 1 |
| Wakabayashi, M | 1 |
| Sakasegawa, N | 1 |
| Kodaka, Y | 2 |
| Ueki, N | 1 |
| Gudis, K | 2 |
| Kawamoto, C | 1 |
| Iwakiri, K | 2 |
| Haddad, I | 2 |
| Kierkus, J | 2 |
| Tron, E | 2 |
| Ulmer, A | 2 |
| Hu, P | 2 |
| Sloan, S | 2 |
| Silber, S | 2 |
| Leitz, G | 1 |
| Leitz, GJ | 1 |
| Kawagoe, T | 1 |
| Maruki, Y | 1 |
| Hashimoto, S | 1 |
| Nagoya, H | 1 |
| Sato, H | 1 |
| Akamizu, T | 1 |
| Sakamoto, C | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multi-Center, Double-Blind, Parallel-Group Study to Evaluate Short-term Safety and Efficacy and Long-Term Maintenance of Two Dose Levels of Rabeprazole Sodium Delayed-Release Pediatric Bead Formulation in 1- to 11-Year Old Pediatric Subjects With Endosc[NCT00787891] | Phase 3 | 127 participants (Actual) | Interventional | 2009-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The Hetzel and Dent Classification grades range from 0 (normal esophageal mucosa, no abnormalities noted) to 4 (deep ulcers anywhere in the esophagus or ulceration of more than half of the esophageal mucosa). Higher observed scores indicate more serious condition. For change of baseline, a score of 0 indicates no change; a positive score indicates the condition is worsening, while a negative score indicates an improvement. (NCT00787891)
Timeframe: Baseline, Week 36
| Intervention | Scores on a scale (Mean) |
|---|---|
| Rabeprazole Sodium 0.5 mg/kg | 0.2 |
| Rabeprazole Sodium 1.0 mg/kg | 0.2 |
The Hetzel and Dent Classification grades range from 0 (normal esophageal mucosa, no abnormalities noted) to 4 (deep ulcers anywhere in the esophagus or ulceration of more than half of the esophageal mucosa). Higher observed scores indicate more serious condition. For change of baseline, a score of 0 indicates no change; a positive score indicates the condition is worsening, while a negative score indicates an improvement. (NCT00787891)
Timeframe: Baseline, Week 12
| Intervention | Scores on a scale (Mean) |
|---|---|
| Rabeprazole Sodium 0.5 mg/kg | -1.3 |
| Rabeprazole Sodium 1.0 mg/kg | -1.0 |
The gastroesophageal reflux disease (GERD) symptom and severity scale measures the frequency (0= Never; 1= 1-2 times; 2= 3-4 times; 3= 5-6 times; 4= 7 or more times) and the severity (1= Mild; 2= Moderate; 3=Severe) of GERD symptoms. The score is defined as the sum of the frequency (0-4) and severity (1-3) of that symptom. The total score is the sum of the scores of all the symptoms and ranges from 12 to 84. Higher scores indicate more serious condition. For change from baseline, 0 indicates no change; a positive score indicates worsening, while a negative score indicates improvement. (NCT00787891)
Timeframe: Baseline, Week 36
| Intervention | Scores on a scale (Mean) |
|---|---|
| Rabeprazole Sodium 0.5 mg/kg | -2.9 |
| Rabeprazole Sodium 1.0 mg/kg | -1.4 |
The gastroesophageal reflux disease (GERD) symptom and severity scale measures the frequency (0= Never; 1= 1-2 times; 2= 3-4 times; 3= 5-6 times; 4= 7 or more times) and the severity (1= Mild; 2= Moderate; 3=Severe) of GERD symptoms. The score is defined as the sum of the frequency (0-4) and severity (1-3) of that symptom. The total score is the sum of the scores of all the symptoms and ranges from 12 to 84. Higher scores indicate more serious condition. For change from baseline, 0 indicates no change; a positive score indicates worsening, while a negative score indicates improvement. (NCT00787891)
Timeframe: Baseline, Week 12
| Intervention | Scores on a scale (Mean) |
|---|---|
| Rabeprazole Sodium 0.5 mg/kg | -11.5 |
| Rabeprazole Sodium 1.0 mg/kg | -8.5 |
Healing is defined as macroscopically normal esophageal mucosa or histologic normal esophageal mucosa. (NCT00787891)
Timeframe: 12 weeks
| Intervention | Percentage of participants (Number) |
|---|---|
| Rabeprazole Sodium 0.5 mg/kg | 78 |
| Rabeprazole Sodium 1.0 mg/kg | 83 |
Healing is defined as macroscopically normal esophageal mucosa or histologic normal esophageal mucosa. (NCT00787891)
Timeframe: 36 weeks
| Intervention | Percentage of patients (Number) |
|---|---|
| Rabeprazole Sodium 0.5 mg/kg | 92 |
| Rabeprazole Sodium 1.0 mg/kg | 88 |
3 trials available for rabeprazole and Abdominal Pain
| Article | Year |
|---|---|
Efficacy and safety of rabeprazole in children (1-11 years) with gastroesophageal reflux disease.
Topics: Abdominal Pain; Body Weight; Child; Child, Preschool; Diarrhea; Dose-Response Relationship, Drug; Es | 2013 |
Maintenance of efficacy and safety of rabeprazole in children with endoscopically proven GERD.
Topics: Abdominal Pain; Child; Child, Preschool; Diarrhea; Double-Blind Method; Endoscopy, Gastrointestinal; | 2014 |
Improvement of meal-related symptoms and epigastric pain in patients with functional dyspepsia treated with acotiamide was associated with acylated ghrelin levels in Japan.
Topics: Abdominal Pain; Acylation; Adolescent; Adult; Aged; Aged, 80 and over; Benzamides; Biomarkers; Drug | 2016 |
2 other studies available for rabeprazole and Abdominal Pain
| Article | Year |
|---|---|
Camostat Mesilate, Pancrelipase, and Rabeprazole Combination Therapy Improves Epigastric Pain in Early Chronic Pancreatitis and Functional Dyspepsia with Pancreatic Enzyme Abnormalities.
Topics: Abdominal Pain; Aged; Benzamides; Drug Therapy, Combination; Dyspepsia; Esters; Female; Gabexate; Ga | 2019 |
Rabeprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abdominal Pain; Adenosine Triphosphatases; Anti-Ulcer Agent | 1999 |